Skip to content

Clinical observation on the treatment of locally advanced cervical cancer by recombinant human adenovirus type 5 injection (H101) combined with radiotherapy and chemotherapy

Clinical observation on the treatment of locally advanced cervical cancer by recombinant human adenovirus type 5 injection (H101) combined with radiotherapy and chemotherapy

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-15006142
Enrollment
Unknown
Registered
2015-03-23
Start date
2015-03-24
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

trial group:Use Oncorine

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. It was diagnosed as cervical cancer according to histopathology. Locally advanced cervical cancer patients haven't radiotherapy and chemotherapy history; 2. Diameter of tumor on CT image was bigger than 6cm; 3. Age: 18 – 65 years old; 4. Karnofsky >=60; 5. Blood routine examination is normal. And coagulation and hemorrhage disorders are not serious; 6. Patients could understand aims of the trial and take part in it voluntarily and sign informed consent; 7. Important organs' function, such as heart, lung, liver, kidney, don't have serious disorder. And radiotherapy and chemotherapy could be tolerant.

Exclusion criteria

Exclusion criteria: 1. Other malignancies are presence at the same time. And it hasn't been cure; 2. Active infection patients in clinical; 3. Allergy history in biologics; 4. Women are in pregnant or in lactation; 5.Have serious internal diseases. Biotherapy, radiotherapy and chemotherapy could not be tolerant; 6. Antiviral drugs and targeted drugs are being using; 7. Large doses of glucocorticoids or other immunosuppressants are used in one month; 8. HIV-positive or other acquired, congenital immunodeficiency diseases. Has organ transplant history.

Design outcomes

Primary

MeasureTime frame
objective efficacy;

Secondary

MeasureTime frame
objective response rate;PFS;OS;

Countries

China

Contacts

Public ContactHua Yu
zhangxiang@zjcc.org.cn+86 0571-88122042

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026